WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H596746
CAS#: 169512-56-5
Description: RPR-109891 is a pseudo-tetrapeptide.
Hodoodo Cat#: H596746
Name: RPR-109891
CAS#: 169512-56-5
Chemical Formula: C26H45N5O6
Exact Mass: 523.34
Molecular Weight: 523.670
Elemental Analysis: C, 59.63; H, 8.66; N, 13.37; O, 18.33
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: RPR-109891; RPR 109891; RPR109891; Klerval;
IUPAC/Chemical Name: (S)-3-(2-aminoacetamido)-4-((S)-3-cyclohexyl-2-(N-ethyl-4-(piperidin-4-yl)butanamido)propanamido)-4-oxobutanoic acid
InChi Key: FUKJLYKZNWGGKO-SFTDATJTSA-N
InChi Code: InChI=1S/C26H45N5O6/c1-2-31(23(33)10-6-9-18-11-13-28-14-12-18)21(15-19-7-4-3-5-8-19)26(37)30-25(36)20(16-24(34)35)29-22(32)17-27/h18-21,28H,2-17,27H2,1H3,(H,29,32)(H,34,35)(H,30,36,37)/t20-,21-/m0/s1
SMILES Code: O=C(NC([C@H](CC(O)=O)NC(CN)=O)=O)[C@H](CC1CCCCC1)N(CC)C(CCCC2CCNCC2)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 523.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA; AFIRME Investigators. Antagonism of the Fibrinogen Receptor after Myocardial Events. Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. Am J Cardiol. 2001 Aug 1;88(3):236-42. PubMed PMID: 11472700.
2: Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000 Jul;140(1):81-93. PubMed PMID: 10874267.
3: Weiss DJ, Mirsky ML, Evanson OA, Fagliari J, McClenahan D, McCullough B. Platelet kinetics in dogs treated with a glycoprotein IIb/IIIa peptide antagonist. Toxicol Pathol. 2000 Mar-Apr;28(2):310-6. PubMed PMID: 10805149.
